查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1250770

到 2028 年的多汗症治疗市场预测 - 按治疗类型、疾病类型、最终用户和地区进行的全球分析

Hyperhidrosis Treatment Market Forecasts to 2028 - Global Analysis By Treatment Type, Disease Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2022 年全球多汗症治疗市场规模将达到 6161 亿美元，预计到 2028 年将达到 9298 亿美元，预测期内復合年增长率为 7.1%。

不一定由热或劳累引起的过度出汗被称为多汗症。您可能会大量出汗，渗出衣服或从手上滴落。出汗过多会毁了你的一天，并导致社交焦虑和尴尬。多汗症的治疗通常从止汗剂开始有效。继发性多汗症患病率上升、市场进入者增加研发支出是推动多汗症治疗市场增长的关键因素。

发表在《Scientific Reports》杂誌上的一项 2021 年研究报告称，与条件相同但接受不同治疗的人相比，在四个不同部位接受肉毒桿菌毒素注射的人报告的焦虑迹像要少得多。

市场动态

促进者

增加研发活动和战略伙伴关係

与该领域相关的最新研究和开发计划在世界范围内越来越受欢迎。例如，Brickell Biotech Inc. 报告了关键的 3 期 Cardigan I 和 Cardigan II 试验的积极结果，该试验评估了 15% 的软□溴铵凝胶作为原发性腋窝多汗症患者每日一次的局部製剂。我们发布了顶级结果并推动市场生长。患有多汗症的患者寻求提供合理和有益缓解的家庭疗法，尤其是儿童。然而，与各种行业参与者和组织的战略伙伴关係和合作正在推动市场增长。

阻碍因素

成本高

治疗程序的高成本阻碍了市场的扩大。由于缺乏可接受的支付计划或组织的特殊考虑，患者往往无法采用这些高端治疗，从而对健康产生重大影响。因此，这是必须解决的固有限制。此外，治疗可能会增加代偿性出汗，阻碍市场增长。

机会

多汗症患者增加

这种疾病在美国的患病率估计约为 3%。多汗症会导致情绪、心理、社交和职业困难。因此，预计多汗症患病率的增加将增加对治疗的需求，从而导致市场增长。Onabotulinum 毒素 A 可用于治疗较小身体区域（例如腋窝、手、脚、头和脸）的过度出汗。保妥适已被证明可显着减少 82-87% 的出汗。它是市场领先的，因为它在治疗后 2-4 天内显示结果，并在 2 週内完全生效。

威胁

副作用

保妥适有很多副作用。肌肉无力、眼部问题和呼吸困难等副作用会严重困扰患者并阻碍市场扩张。此外，潜在的副作用包括口干、视力模糊和膀胱问题。背部、腹部、大腿和腿部出汗过多是最令人不快的副作用，阻碍了市场。

COVID-19 的影响

预计 COVID-19 大流行将减缓全球多汗症药物市场的增长。然而，在大流行期间，儘管有避免社会孤立的警告，但许多人还是采取了自我药疗和其他替代方法来治疗他们的疾病。在大流行期间，多汗症患者患抑郁症的风险异常高，尤其是女性患者，其中一些患者报告难以获得治疗。

预计在预测期内手术治疗部分将是最大的

由于专业的汗液测试以查看出汗量是否在正常范围内，估计外科治疗领域将出现有利可图的增长。医务人员使用非手术方法治疗多汗症，包括止汗剂、肌肉鬆弛剂注射和药物治疗。然而，这些治疗只能短期缓解症状。使用小型内窥镜和谐波刀片切除过度活跃的神经节段。这种巧妙的刀片以高频振动并产生很少的热量，从而保护邻近的神经。手术可以长期缓解过度出汗。手术引起的多汗症需要3mm以下的切口，神经的可视性提高，手术的精度提高，手术的痛苦减轻，恢復时间缩短，问题也少，因此侵入性小。我们正在促进市场的发展，因为有不是这样的东西

预计原发性局灶性多汗症部分将在预测期内见证最高的复合年增长率。

预计原发性局灶性多汗症部分将在预测期内呈现最快的复合年增长率。这是因为处方止汗剂可能会开出含有氯化铝的止汗剂。神经阻断药、处方药膏和湿巾用于有效治疗腋窝、手掌和脚底。其他受影响的区域包括面部、头皮、腹股沟和乳腺下腺。原发性多汗症是由使小汗腺过度劳累的错误神经信号引起的。症状通常出现在手掌、脚底、腋窝，有时还会出现在面部。

市场占有率最高的地区

北美将在 2021 年占据全球多汗症治疗市场份额的大部分，预计在预测期内占据最大的市场份额，并预计在预测期内保持其主导地位。这是由于多汗症治疗技术的进步、患病率的上升以及关键而强大的医疗基础设施的可用性。预计这一数字将显着增长。

复合年增长率最高的地区：

由于以下原因，预计欧洲在预测期内的复合年增长率最高。该地区原发性和继发性多汗症的高患病率可能会导致广泛的治疗。由于患病率高，一些治疗药物在该地区使用较多，例如商业六水合氯化铝 20.0%。这样的优势会增加产品的消费需求，带来市场的扩大。原发性多汗症、癌症、心血管疾病、继发性多汗症的增加、技术的改进以及该地区重要市场进入者的存在正在促进增长。

市场的重要参与者

多汗症治疗市场的主要参与者包括 Brickell Biotech Inc、Eli Lilly and Company、AbbVie Inc、1315 Capital、Merz Pharma、Dermadry Laboratories Inc、Dermata Therapeutics Inc、Advin Health Care、Dermavant Sciences Inc、TheraVida、NovaMedica、Eirion Therapeutics, Inc 、Roivant Sciences Ltd、GSK Plc、GlaxoSmithKline PLC 和 Sesderma。

重大发展

2023 年 1 月，AbbVie 和 Anima Biotech 宣布合作发现和开髮用于癌症和免疫靶标的 mRNA 生物调节剂。Anima 将使用其 mRNA 闪电平台发现针对联合品牌目标的新型 mRNA 生物调节剂，并将向 AbbVie 提供许可、进一步开发和商业化该项目的独家权利。

2022年12月，AbbVie启动与HotSpot Therapeutics的战略合作，进一步拓展免疫学管线，与HotSpot合作为患有严重自身免疫性疾病的患者提供全新的靶向类调节剂成为可能。

2022 年 12 月，Dermavant 推出了第一个 VTAMA(R) (Tapinalof) Cream 1% 商业广告，作为针对成年寻常型银屑病患者的全国性多媒体宣传活动的一部分。许多人等待 VTAMA 乳膏等不同的寻常型银屑病药物已等待很长时间。

2022 年 6 月，Dermata 宣布最后一名患者参加了每週一次的 DMT310 治疗中度至重度酒渣鼻的 2 期试验，DMT310 适用于治疗多种炎症性皮肤病，包括我目前正在研究的酒渣鼻、痤疮和牛皮癣。

本报告内容

  • 区域和国家细分市场份额评估
  • 对新进入者的战略建议
  • 涵盖 2020、2021、2022、2025 和 2028 年的市场数据
  • 市场驱动因素（市场趋势、制约因素、机会、威胁、挑战、投资机会/建议等）
  • 基于市场估计的关键业务领域的战略建议
  • 竞争格局和趋势
  • 公司概况，包括详细战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 主要参与者的SWOT分析（最多3人）
  • 区域部分
    • 应客户要求提供主要国家的市场预估、预测和CAGR（注：通过可行性检查）
  • 竞争标桿
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

目录

第一章内容提要

第二章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 促进者
  • 抑製剂
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5 全球多汗症治疗市场，按治疗类型

  • 手术治疗
  • 局部治疗
  • 肉毒素A
  • 激光疗法
  • 离子电渗疗法
  • 其他治疗类型

6 全球多汗症治疗市场，按疾病类型

  • 原发性局灶性多汗症
  • 继发性全身性多汗症

7. 全球多汗症治疗市场，按最终用户分类

  • 医院
  • 家庭护理
  • 专科中心
  • 其他最终用户

8.按地区分列的全球多汗症治疗市场

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东

第九章主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十章公司简介

  • Brickell Biotech Inc.
  • Eli Lilly and Company
  • AbbVie Inc
  • 1315 Capital
  • Merz Pharma
  • Dermadry Laboratories Inc.
  • Dermata Therapeutics Inc.
  • Advin Health Care
  • Dermavant Sciences Inc.
  • TheraVida
  • NovaMedica
  • Eirion Therapeutics, Inc
  • Roivant Sciences Ltd
  • GSK Plc
  • GlaxoSmithKline PLC
  • Sesderma
Product Code: SMRC22647

According to Stratistics MRC, the Global Hyperhidrosis Treatment Market is accounted for $616.1 billion in 2022 and is expected to reach $929.8 billion by 2028 growing at a CAGR of 7.1% during the forecast period. Excessive sweating that is not necessarily caused by heat or exertion is known as hyperhidrosis. Sweating so intensely that it soaks through your clothes or drips off your hands is possible. Sweating excessively can ruin your day and cause social anxiety and shame. Treatment for hyperhidrosis is usually effective it usually starts with antiperspirants. The rise in the prevalence of secondary hyperhidrosis disorders, as well as the increase in research and development expenditure by market participants, are significant drivers driving the growth of the hyperhidrosis treatment market.

According to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions.

Market Dynamics:

Driver:

Increasing R&D activity and strategic partnerships

The most recent R&D initiatives related to the sector are gaining popularity around the world. Brickell Biotech Inc., for example, announced favourable topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies that assessed sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis this increases market growth. Patients suffering from hyperhidrosis want home treatments that provide reasonable and beneficial relief, particularly for children. However strategic partnerships and collaborations between various industry companies and organisations are assisting in market growth.

Restraint:

High cost

The high cost of treatment procedures stifles market expansion. Patients frequently fail to adopt these high-end treatment alternatives due to a lack of acceptable payment plans and special considerations by organisations, which have a significant impact on their health. As a result, this is an essential constraint that must be addressed. Moreover, the treatment may lead to the increased compensatory sweating which hampers the market growth.

Opportunity:

Rise in hyperhidrosis case

The prevalence of this illness in the United States is estimated to be around 3%. Hyperhidrosis can cause emotional, psychological, social, and vocational difficulties. As a result, the increased prevalence of hyperhidrosis is predicted to enhance demand for therapy and consequently market growth. Onabotulinumtoxin A can be used to treat excessive sweating in the armpits, hands, feet, head, and face, as well as other relatively tiny body locations. Botox has been demonstrated to significantly reduce perspiration by 82-87%. The benefits appear 2 to 4 days after treatment, with the full results evident within two weeks thereby propelling the market.

Threat:

Side effects

Botox is connected with a number of adverse effects. Consequences such as muscle weakness, eye problems, and breathing difficulties are significantly hurting patients and stifling market expansion. Furthermore, potential adverse effects include dry mouth, impaired vision, and bladder issues. Excessive sweating on the back, belly, thighs, or lower legs is the most unpleasant side effect which hampers the market.

Covid-19 Impact

The COVID-19 pandemic is expected to slow the growth of the global market for hyperhidrosis remedies. During the pandemic, however, many individuals treated their ailments via self-medication or other alternative ways, despite warnings to keep social isolation. During the pandemic, individuals with hyperhidrosis had a disproportionately greater risk of depression, particularly among female patients, and some of these patients reported difficulty accessing therapy.

The Surgical treatments segment is expected to be the largest during the forecast period

The Surgical treatments segment is estimated to have a lucrative growth, due to its specialist sweat test that can assist establish if the amount of perspiration your body produces is within normal limits. Medical professionals addressed hyperhidrosis with nonsurgical approaches such as antiperspirants, muscle relaxing injections, and medicines. These treatments only provide short relief from symptoms. Using a small endoscope and a harmonic blade, remove a segment of the hyperactive nerve. This clever blade vibrates at high frequencies and produces little heat, protecting adjacent nerves. Surgery provides long-term relief from excessive sweating. Surgical hyperhidrosis less invasive incisions of less than three millimetres, improved nerve vision for more precise surgery, reduced surgical pain, a shorter recovery period, and no problems there by encouraging in the market growth.

The Primary focal hyperhidrosis segment is expected to have the highest CAGR during the forecast period

The Primary focal hyperhidrosis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to antiperspirant on prescription doctor may prescribe an antiperspirant containing aluminium chloride. Medication that blocks nerves, prescribed creams and wipes are used to effectively treat the axillae, palms, and soles are commonly affected by primary focal hyperhidrosis. Other locations that may be affected include the face, scalp, inguinal, and inframammary areas. Primary hyperhidrosis is produced by incorrect nerve signals, which cause eccrine sweat glands to overwork. It typically affects the palms, soles, underarms, and occasionally the face.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to a majority of the worldwide hyperhidrosis treatment market share in 2021 and is predicted to continue dominant during the forecast period. This is due to technological advances in hyperhidrosis treatment, a elevated incidence of disease, and the availability of critical and robust medical infrastructure in the region to see significant growth as the patient population grows, healthcare infrastructure develops, and investment initiatives in the region expand.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to The high frequency of primary and secondary hyperhidrosis in the region will increase treatment uptake. Because of the high prevalence, several therapies, such as over-the-counter aluminium chloride hexahydrate 20.0% in the region, have seen greater use. Such predominance will enhance demand for product consumption, resulting in market expansion. The increasing burden of primary hyperhidrosis, cancer, and cardiovascular problems, rises in secondary hyperhidrosis, technological improvements, and the existence of important market participants in the region are all contributing to the growth.

Key Players in the market

Some of the key players profiled in the Hyperhidrosis Treatment Market include Brickell Biotech Inc, Eli Lilly and Company, AbbVie Inc, 1315 Capital, Merz Pharma, Dermadry Laboratories Inc, Dermata Therapeutics Inc., Advin Health Care, Dermavant Sciences Inc, TheraVida, NovaMedica, Eirion Therapeutics, Inc, Roivant Sciences Ltd, GSK Plc, GlaxoSmithKline PLC and Sesderma

Key Developments:

In Jan 2023, AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets, Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

In Dec 2022, AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline this collaboration with HotSpot has the potential to deliver an entirely new target class of modulators to patients with serious autoimmune diseases

In Dec 2022, Dermavant Launched First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

In June 2022, Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea, DMT310 is currently being investigated to treat multiple inflammatory skin conditions, including rosacea, acne, and psoriasis.

Treatment Types Covered:

  • Surgical Treatments
  • Topical Treatments
  • Botulin Toxin A
  • Laser Treatments
  • Iontophoresis
  • Other Treatment Types

Disease Types Covered:

  • Primary Focal Hyperhidrosis
  • Secondary Generalized Hyperhidrosis

End Users Covered:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperhidrosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Surgical Treatments
  • 5.3 Topical Treatments
  • 5.4 Botulin Toxin A
  • 5.5 Laser Treatments
  • 5.6 Iontophoresis
  • 5.7 Other Treatment Types

6 Global Hyperhidrosis Treatment Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Primary Focal Hyperhidrosis
  • 6.3 Secondary Generalized Hyperhidrosis

7 Global Hyperhidrosis Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Homecare
  • 7.4 Speciality Centres
  • 7.5 Other End Users

8 Global Hyperhidrosis Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Brickell Biotech Inc.
  • 10.2 Eli Lilly and Company
  • 10.3 AbbVie Inc
  • 10.4 1315 Capital
  • 10.5 Merz Pharma
  • 10.6 Dermadry Laboratories Inc.
  • 10.7 Dermata Therapeutics Inc.
  • 10.8 Advin Health Care
  • 10.9 Dermavant Sciences Inc.
  • 10.10 TheraVida
  • 10.11 NovaMedica
  • 10.12 Eirion Therapeutics, Inc
  • 10.13 Roivant Sciences Ltd
  • 10.14 GSK Plc
  • 10.15 GlaxoSmithKline PLC
  • 10.16 Sesderma

List of Tables

  • Table 1 Global Hyperhidrosis Treatment Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 3 Global Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 4 Global Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 5 Global Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 6 Global Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 7 Global Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 8 Global Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 9 Global Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 10 Global Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 11 Global Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 12 Global Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 13 Global Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 14 Global Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 15 Global Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 16 Global Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 17 North America Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 18 North America Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 19 North America Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 20 North America Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 21 North America Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 22 North America Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 23 North America Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 24 North America Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 25 North America Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 26 North America Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 27 North America Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 28 North America Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 29 North America Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 30 North America Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 31 North America Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 32 North America Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 33 Europe Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 34 Europe Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 35 Europe Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 36 Europe Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 37 Europe Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 38 Europe Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 39 Europe Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 40 Europe Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 41 Europe Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 42 Europe Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 43 Europe Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 44 Europe Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 45 Europe Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 46 Europe Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 47 Europe Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 48 Europe Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 49 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 50 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 51 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 52 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 53 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 54 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 55 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 56 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 57 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 58 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 59 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 60 Asia Pacific Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 61 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 62 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 63 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 64 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 65 South America Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 66 South America Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 67 South America Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 68 South America Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 69 South America Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 70 South America Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 71 South America Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 72 South America Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 73 South America Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 74 South America Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 75 South America Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 76 South America Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 77 South America Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 78 South America Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 79 South America Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 80 South America Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 81 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 83 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 84 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 85 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 86 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 87 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 88 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 89 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 90 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 91 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 92 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 93 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 94 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 95 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 96 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)